# TEM: AI healthcare product progress or hype premium?

> Tempus AI has fresh attention around FDA-cleared genomics and cardiac AI progress, but the stock remains down sharply year to date. The thesis depends on whether regulated clinical products can convert into durable adoption, revenue scale, and margin improvement before losses and valuation risk dominate.

**Companies**: Tempus AI, Inc. - Class A Common Stock
**Sectors**: Technology
**Published**: 2026-06-18
**Last Updated**: 2026-06-18
**Source**: https://thesisloop.ai/thesis/70547e7b-7997-44a7-bff2-ee14cc8fed77

## Score Overview

| Company | Management | Business Model | Future Growth | Risk |
|---------|-----------|---------------|--------------|------|
| Tempus AI, Inc. - Class A Common Stock | 67/100 | 77/100 | 62/100 | 71/100 |

## Tempus AI, Inc. - Class A Common Stock (NASDAQ:TEM)

**Sector**: Technology | **Industry**: Software & Cloud Platforms

### Management Credibility

- **[PRINCIPLE] GAAP to Cash Quality Matters** (POSITIVE, MET): The company significantly exceeded the minimum liquidity requirement of $25 million, reporting $660.5 million in cash, cash equivalents, and restricted cash as of September 30, 2025. (1 met across 1 tracked commitment)
  > The Company is required to maintain a minimum liquidity of at least $25 million... The Company was in compliance with all covenants in the Credit Agreement as of September 30, 2025.
- **[CATALYST] Operating Margin Reset** (NEUTRAL, MET): R&D expenses increased from $119.7 million to $122.5 million for the nine months ended September 30, 2025, compared to the prior year period, confirming the absolute dollar growth trend. (1 met across 1 tracked commitment)
  > These expenses, though expected to increase in absolute dollars, are expected to decrease modestly as a percentage of revenue in the long term, though they may fluctuate as a percentage from period to period due to the timing and extent of these expenses.
- **[PRINCIPLE] Platform Consolidation Beats Point-Tool Growth** (NEUTRAL, IN_PROGRESS): The commitment remains active through December 31, 2026. The company continues to provide services under this agreement, though specific cumulative spend to date against the $220 million floor is not explicitly totaled in this quarter's report. (1 in progress across 1 tracked commitment)
  > AstraZeneca has committed to spend a minimum of $220 million on such products and services during the term of the MSA. The term of the MSA will continue through December 31, 2026.
- **[CATALYST] RPO or CRPO Reacceleration** (NEGATIVE, REVISED): Management has lowered the percentage of RPO expected to be recognized over the next 12 months from 59% (as of March 2025) to 49% as of September 30, 2025, suggesting a lengthening of contract fulfillment timelines. (1 revised across 1 tracked commitment)
  > The Company’s remaining performance obligations related to multi-year contracts was $360.2 million as of September 30, 2025, of which the Company expects to recognize approximately 49% as revenue over the next year.
- **[METRIC] RPO, Billings, and Backlog** (NEUTRAL, IN_PROGRESS): The agreement is active with $70 million paid upon execution. The commitment floor of $180 million remains in effect through 2027. (4 in progress across 4 tracked commitments)
  > In exchange for certain discounted prices, GSK has committed to spend a minimum of $180 million on such products and services during the term of the GSK Agreement... The term of the GSK Agreement will continue through December 31, 2027
- The company has successfully transitioned to a large accelerated filer as indicated on the cover page of the Q1 2026 report. (1 met across 1 tracked commitment) (POSITIVE, MET)
  > Based on the aggregate market value of shares of the Company’s Class A common stock held by non-affiliates as of June 30, 2025, the Company expects to become a “large accelerated filer” and no longer qualify as an emerging growth company as of December 31, 2025.
- **[METRIC] Sales Efficiency and CAC Payback** (NEGATIVE, REVISED): SG&A expenses increased significantly in absolute dollars ($212.6M vs $154.6M YoY) and also increased as a percentage of revenue (61.1% in Q1 2026 vs 60.5% in Q1 2025), contrary to the long-term goal of modest percentage decreases. (1 revised across 1 tracked commitment)
  > Selling, general and administrative 212,594 [for 2026] 154,627 [for 2025] ... Total net revenue 348,116 [for 2026] 255,737 [for 2025]
- **[PRINCIPLE] AI Monetization Must Show in Usage or ARPU** (NEUTRAL): Pathos is committed to paying the company $200 million in data license fees over a three-year period. — target: $200 million (+2 more commitments)
  > (iii) Pathos will pay the Company data license fees of $200 million over a three-year period, including an upfront payment of $50 million paid as of April 2025
- **[PRINCIPLE] Cloud Infrastructure Cost Discipline** (NEUTRAL): Management expects technology research and development expenses to increase in absolute dollars for the foreseeable future. — target: Increase in absolute dollars (+1 more commitment)
  > We expect that technology research and development expenses will increase in absolute dollars for the foreseeable future as we continue to invest to support these activities.
- **[TREND] Vertical AI Applications** (POSITIVE, IN_PROGRESS): The company has received the initial $50 million upfront payment as of April 2025 and has recognized $41.7 million in revenue from Pathos for the nine months ended September 30, 2025. (2 in progress across 2 tracked commitments)
  > We expect to maintain high levels of investment in product innovation over the coming years as we continue to develop new laboratory assays, develop algorithms, and expand our Platform into new disease areas.

### Business Model

- The vast majority of the company's revenue is generated within North America, specifically the United States. (NEUTRAL)
  > The majority of the Company’s revenue is generated in North America.
- **[CATALYST] M&A or Activist Pressure** (POSITIVE, Change: EXPANDING): The Genomics segment (formerly Diagnostics) saw massive expansion, primarily driven by the acquisition of Ambry Genetics in February 2025, which contributed $97.3 million in the quarter. Organic oncology test volume also grew from 66,500 to 84,000 tests. (2 expanding)
  > Genomics revenue of $241,843 for the three months ended June 30, 2025... an increase of 115%... primarily due to an increase in the number of Oncology tests and the addition of Hereditary tests through the acquisition of Ambry.
- **[CATALYST] Major Platform Release** (POSITIVE, Change: SHIFTED): The company's proprietary position was bolstered by the acquisition of Paige.AI, an AI company specializing in digital pathology, and the launch of a $200 million Foundation Model development project with Pathos. (1 expanding, 1 shifted)
  > Paige is an AI company specializing in digital pathology. The Paige Acquisition is expected to allow the Company to grow its dataset and establish a strong footprint in digital pathology with an industry leading technology portfolio.
- **[METRIC] RPO, Billings, and Backlog** (POSITIVE, Change: EXPANDING): The moat is strengthening as the company successfully 'commercializes records multiple times.' Data generated in the lab (Diagnostics) is structured and licensed to pharma partners (Data), creating a self-reinforcing loop of clinical and molecular data growth. (1 expanding)
  > We are able to commercialize records multiple times, both at the time a test is run and thereafter... The data generated in our lab or ingested into our platform as part of the Diagnostics product line is structured and de-identified, prior to commercialization.
- **[PRINCIPLE] AI Monetization Must Show in Usage or ARPU** (POSITIVE, Change: EXPANDING): The Data and Applications segment grew 31% year-over-year, driven by increased demand for 'Insights' products (de-identified data licensing) and new customer adoption. Revenue share shifted slightly downward to 25% of total revenue due to the faster inorganic growth in the Diagnostics segment. (3 expanding across 2 engines)
  > Data and applications 87,018 ... 41% ... The increase in Data and applications revenue for the three months ended March 31, 2026, compared to the same period in 2025, was driven primarily by an increase of $21.8 million and $3.0 million from increased demand for our Insights and Next products, respe
- **[PRINCIPLE] Platform Consolidation Beats Point-Tool Growth** (POSITIVE, Change: EXPANDING): The company significantly expanded its proprietary technology moat through the acquisition of Ambry (hereditary cancer screening) and Deep 6 AI (clinical trial matching), adding substantial developed technology assets and customer relationships. (3 expanding)
  > Each product line is designed to enable and enhance the other, thereby creating network effects in each of the markets in which we operate. We are able to commercialize records multiple times, both at the time a test is run and thereafter.
- **[TREND] Vertical AI Applications** (POSITIVE, Change: EXPANDING): The Data and services segment grew 36% year-over-year, largely due to a $16.5 million increase in demand for 'Insights' products, specifically the Pathos Foundation Model agreement. (4 expanding)
  > Unlike traditional diagnostic labs, we can incorporate unique patient information, such as clinical, molecular, and imaging data... we built both a technology platform to free healthcare data from silos and an operating system to make this data useful, the combination of which we refer to as our Pla

### Future Growth

- Tempus is expanding its reach into the Japanese market through a joint venture with SoftBank, which includes a data licensing agreement already generating revenue. (NEUTRAL)
  > SB Tempus will engage in certain business activities in Japan similar to those conducted by the Company in the United States... For each of the three months ended March 31, 2026 and 2025, the Company recognized $6.2 million in Data and applications revenue related to the Data License Agreement.
- **[CATALYST] M&A or Activist Pressure** (POSITIVE, Trend: NEW_TREND): The company is actively pursuing a new trend of inorganic growth through major acquisitions, specifically the pending $375 million acquisition of Ambry Genetics. (5 new trend across 5 signals, 1 leading indicator)
  > The Paige Acquisition is expected to allow the Company to grow its dataset and establish a strong footprint in digital pathology with an industry leading technology portfolio.
- **[CATALYST] Operating Margin Reset** (POSITIVE, Trend: ACCELERATING): Adjusted EBITDA losses are narrowing consistently, showing a 15.6% improvement in Q2 2024 compared to Q2 2023, indicating a trend toward operational break-even. (5 accelerating across 5 signals)
  > Adjusted EBITDA was $(2,833) thousand for the three months ended March 31, 2026, compared to $(16,174) thousand for the three months ended March 31, 2025.
- **[METRIC] RPO, Billings, and Backlog** (POSITIVE, Trend: STEADY): The company maintains a strong backlog of non-cancelable multi-year contracts. While the total RPO is reported at $194.3 million for these specific long-term deals, the company expects to recognize 59% of this as revenue within the next 12 months, indicating strong near-term visibility. (2 new trend, 3 steady across 5 signals)
  > The Company’s remaining performance obligations related to multi-year contracts was $378.4 million as of March 31, 2026, of which the Company expects to recognize approximately 50% as revenue over the next year.
- **[PRINCIPLE] AI Monetization Must Show in Usage or ARPU** (POSITIVE, Trend: ACCELERATING): Data and services revenue is accelerating, with Q2 2024 growth (32%) outpacing the full first-half growth rate (31%), driven by high demand for 'Insights' products. (3 accelerating, 2 steady across 5 signals)
  > Data and applications revenue increased $25.1 million, or 41%, for the three months ended March 31, 2026 compared to the same period in 2025.
- **[PRINCIPLE] GAAP to Cash Quality Matters** (NEUTRAL): Growth could be limited by the company's continued reliance on external financing and its significant accumulated deficit as it pursues scale.
  > We have incurred significant losses and negative cash flows from operations since our inception, and as of March 31, 2026, we had an accumulated deficit of $2.5 billion.
- **[TREND] Vertical AI Applications** (POSITIVE, Trend: ACCELERATING): Genomics revenue (diagnostics) is accelerating significantly, nearly doubling year-over-year. This is driven by a 20% increase in oncology test volume and the massive addition of hereditary testing volume following the Ambry acquisition in February 2025. (4 accelerating, 1 steady across 5 signals, 1 leading indicator)
  > The increase in Diagnostics revenue for the three months ended March 31, 2026, compared to the same period in 2025, was primarily due to an increase in the number of Oncology tests and the addition of Hereditary tests through the acquisition of Ambry in February 2025.

### Risk Assessment

- The risk is intensifying as Tempus has filed counterclaims and a separate patent infringement complaint against Guardant, expanding the scope of the legal battle. (5 intensifying, 1 high-severity) (NEGATIVE, Risk: HIGH)
  > The complaint alleges that the Tempus xF, Tempus xF+, Tempus xM Monitor and Tempus xM MRD products use liquid biopsy technology that infringes five Guardant U.S. patents. The complaint seeks injunctive relief, unspecified monetary damages (including enhanced damages), a future mandatory royalty, cos
- **[CATALYST] M&A or Activist Pressure** (NEUTRAL, Risk: MODERATE): The risk is stable as the company continues to integrate Ambry, which contributed $97.3 million in revenue but requires significant amortization and personnel costs. (3 stable, 1 emerging)
  > Total acquisition price [for Ambry] $692,343... The excess of purchase consideration over the fair value of the net assets acquired was recorded as goodwill.
- **[METRIC] Gross Margin and Compute Cost** (NEGATIVE): The risk is stable; while cloud costs rose to $30.4 million for the quarter, management is using principal reductions on a Google note to offset these spends. (1 stable, 2 intensifying)
  > The principal amount is automatically reduced each year based on a formula taking into account the aggregate value of the Google Cloud Platform services used by the Company.
- **[METRIC] SBC, Dilution, and Free Cash Flow** (NEGATIVE): The risk is intensifying due to the issuance of $750 million in new convertible notes in July 2025, significantly increasing the total debt load. (2 intensifying)
  > On July 3, 2025, the Company completed the Offering of $750.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2030.
- **[PRINCIPLE] AI Monetization Must Show in Usage or ARPU** (NEGATIVE): This risk is intensifying as related-party revenue surged to $21.8 million (6.3% of total revenue) from just $0.6 million a year ago, primarily driven by the Pathos Foundation Model agreement. (1 intensifying)
  > Includes related party revenue of $21,823 and $631 for the three months ended March 31, 2026 and 2025, respectively.
- **[PRINCIPLE] Cloud Infrastructure Cost Discipline** (NEGATIVE, Risk: HIGH): The risk is intensifying as cloud and software costs rose to $36.1M in Q3 2025 from $24.7M in Q3 2024. Total cloud costs for the nine-month period reached $93.8M. (1 intensifying)
  > Cloud and software [expenses] $39,333 [for three months ended March 31, 2026] compared to $24,866 [for 2025].
- **[PRINCIPLE] GAAP to Cash Quality Matters** (NEGATIVE, Risk: HIGH): The risk is easing slightly in terms of quarterly loss magnitude ($42.8M in Q2 2025 vs $552.2M in Q2 2024), though the accumulated deficit remains a long-term vulnerability. (1 easing, 2 stable, 1 intensifying, 1 high-severity)
  > We have incurred significant losses and negative cash flows from operations since our inception, and as of March 31, 2026, we had an accumulated deficit of $2.5 billion.
- **[TREND] Vertical AI Applications** (NEGATIVE, Risk: HIGH): The risk is stable but remains high; while Medicare reimbursement rates increased, the company still relies heavily on securing reimbursement to achieve financial performance. (2 stable, 1 intensifying, 1 high-severity)
  > As of December 31, 2025, we had received payment on approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests across all payers performed from January 1, 2023 through December 31, 2024.

### Scenario Analysis

- Tempus AI operates in the precision medicine and healthcare data analytics sector, which is fundamentally driven by clinical research, diagnostic demand, and pharmaceutical R&D partnerships rather than industrial manufacturing or global supply chain logistics. The company's core business model is not structurally exposed to US tariffs, reshoring, or industrial policy incentives, as its primary inputs are digital data and laboratory diagnostics rather than physical goods subject to trade friction. (NEUTRAL)
- A downward shift in the Fed rate cycle reduces the discount rate applied to Tempus's long-dated cash flows, leading to a significant expansion in its growth multiple. This first-order effect on capital costs flows into a second-order surge in biotechnology R&D budgets, directly increasing demand for Tempus's high-margin 'Data and Applications' segment. Ultimately, this creates a third-order structural shift where Tempus can more cheaply fund its $2.5 billion deficit and continue its roll-up strategy of acquiring AI-driven healthcare firms, solidifying its position as a market leader in precision medicine. (POSITIVE)
  > We are exposed to market risk for changes in interest rates related primarily to our cash, cash equivalents and restricted cash, and our indebtedness. As of March 31, 2026, we had $307.7 million outstanding under our Term Loan Facilities and Revolving Credit Facility, which are subject to quarterly 
- 4 positive impacts identified; 2 negative impacts identified (POSITIVE)
  > Outside of the expenses reported on the consolidated statements of operations and comprehensive loss, the CODM regularly reviews personnel costs and cloud costs within selling, general, and administrative expenses... Cloud and software [was] 39,333 [for the three months ended March 31, 2026].

---
*Generated by [ThesisLoop](https://thesisloop.ai) — AI investment research for US equities.*